Cipla Finalizes Inzpera Healthscience Acquisition Deal

Cipla Ltd. had signed binding agreements to purchase the entire shareholding of Inzpera Healthscience Pvt. Ltd. for around Rs 110.65 crore. The acquisition is a clear indication of Cipla's ongoing commitment to broadening the consumer health and wellness division of its business.

Inzpera Healthscience, established in 2016 and based in Mumbai, is a company specializing in the development, production, and marketing of differentiated paediatric pharmaceutical and wellness products. The firm has developed a strong position in the paediatric segment by providing innovative solutions geared towards the improvement of child health and nutrition.

As per Cipla's regulatory filing, the enterprise value of Inzpera is around Rs 120 crore. The final purchase price, after all the necessary working capital adjustments, was set at Rs 110.65 crore, which is the total consideration in the form of equity shares and non-convertible redeemable preference shares representing 100% of Inzpera’s shareholding,

Also Read: Takeda's QDENGA Confirms Long-Term Dengue Protection

According to Cipla, the deal fits in with the company’s long-term plan of strengthening its consumer healthcare division by taking advantage of Inzpera’s niche product portfolio and research capabilities. "It is this strategic decision that intends to link Inzpera’s differentiated paediatric offerings with Cipla’s robust distribution network and operational strength so that scalability and growth can be driven," the company said.

Cipla is now one step closer to dominating the paediatric and wellness segments with the help of this acquisition, thus ramping up its presence not only in the prescription but also in the over-the-counter health categories in India’s fast-evolving healthcare landscape.